This website may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements about the potential of milnacipran to treat FMS and our continued development of milnacipran, and our OSA program. Actual results could vary materially from those described as a result of a number of factors, including those set forth in Cypress Annual Report on Form 10-K, the most recent Quarterly Report on Form 10-Q and any subsequent SEC filings and including, but not limited to, the fact that because we did not achieve statistical significance on our primary endpoints for the first Phase III clinical trial evaluating milnacipran for FMS, that the FDA may not accept the first completed Phase III trial as one of the two pivotal trials required for NDA approval, that the FDA may not allow us to use the baseline observation carry-forward analysis in connection with our first Phase III clinical trial; that upon further analysis of our first phase III clinical trial, that we and Forest may elect not to continue development of milnacipran; that the results from our second Phase III clinical trial may not achieve statistical significance, that Forest may not commence the third planned Phase III clinical trial for milnacipran and that we may not be able to protect our milnacipran related patents and proprietary technology. In addition, there is a risk that we may not be able to realize or successfully develop a product for OSA; the risk that the mirtazapine study at the University of Illinois was conducted on only a very small number of patients and that the results will not be repeated, and that mirtazapine may not be an effective treatment for OSA; that mirtazapine alone or in combination with any other compound may not be safe and effective in patients with OSA; that our intellectual property position for our OSA program may not be useful or defensible; that we may encounter regulatory or other difficulties in developing a product for OSA, especially in light of the fact that a combination drug may be selected for development; and that we may not be successful in identifying, acquiring, licensing and developing any additional product candidates. The Company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the applicable date of any of our statements on this website, except as required by law.